Human volunteers were challenged with Haemophilus ducreyi. Twenty subjects were inoculated with 2 doses (∼30 cfu) of live and 1 dose of heat-killed bacteria at 3 sites on the arm. Eight subjects were assigned to biopsy 1 or 4 days after inoculation, and 12 were biopsied after they developed a painful pustular lesion or were followed until disease resolved. Papules developed at 95% of 40 sites infected with live bacteria (95% confidence interval [CI], 83.1%-99.4%). In 24 sites followed to end point, 27% of the papules resolved, 69% (95% CI, 47.1%-86.6%) evolved into pustules, and 4% remained at the papular stage. Recovery rates of H. ducreyi from surface cultures ranged from 13% to 41%. H. ducreyi was recovered from biopsies of 12 of 15 pustules and 1 of 7 papules, suggesting that H. ducreyi replicates between the papular and pustular stages of disease.
Haemophilus ducreyi causes chancroid, a genital ulcer disease that facilitates transmission of human immunodeficiency virus type 1 [1] [2] [3] [4] [5] . To study H. ducreyi pathogenesis and host responses, we developed an experimental model of H. ducreyi infection in human subjects [6, 7] . In this model, bacterial suspensions are delivered into the skin of the upper arm through puncture wounds made by an allergy testing device. Infection is terminated when a subject develops a painful pustule. In doseresponse studies, 4 volunteers developed pustules at 9 sites inoculated with estimated delivered doses (EDDs) of 130-7000 cfu; however, pustules developed too rapidly to mimic natural infection [6] . Nine subjects were inoculated with EDDs of 1-35 cfu [7] . Inoculation of an EDD of 1-10 cfu at 11 sites led to papule formation at 5 sites, and pustules developed at 4 of these sites. Inoculation of an EDD of 15-35 cfu at 7 sites caused papule and pustule formation at 7 and 5 sites, respectively. Although infection mimicked natural disease [7] , the study lacked power to determine papule and pustule formation rates.
One subject enrolled in the dose-response study developed papules at 2 sites inoculated with EDDs of 8 and 15 cfu [7] . A pustule developed at the site inoculated with 8 cfu, while the papule at the site that received 15 cfu resolved. The data suggest that lesion outcomes at multiple sites infected with the same isolate in an individual subject may be independent events. If confirmed, this observation has implications for the design of trials in which subjects may be inoculated with multiple isolates, such as isogenic mutant-parent comparisons.
Here we describe the standardization of the model of experimental infection using a human-passaged variant of H. ducreyi 35000. We determined the papule and pustule formation rates for a standardized EDD of bacteria and examined whether lesion formation and outcomes could be considered statistically independent in individual subjects.
Methods
Human volunteers. Healthy adult men and women volunteers (≥18 years old) were recruited for the study. Enrollment procedures and exclusion criteria were described in detail elsewhere [6, 7] . Bacteria. Master stocks of H. ducreyi 35000HP (human-passaged) were prepared by expanding a single colony isolated from a subject (C-7) after 13 days of experimental infection with 35000 [7] . In broth, 35000 and 35000HP had identical growth rates. The isolates had identical outer membrane protein and lipooligosaccharide profiles (data not shown).
Inoculation. Bacteria were grown to mid-log phase and processed exactly as described previously [6, 7] . One to 4 volunteers were challenged in 12 different iterations with 2 identical doses of live and 1 dose of heat-killed bacteria at 3 sites on the same arm. Suspensions containing the target dose (1.8-cfu) were 4 4.4 ϫ 10 inoculated into the skin of the upper arm with an allergy testing device [6, 7] . The device delivers ∼1:1000 of solution loaded on its tines into the skin [6, 7] . Thus, the target EDD (18-44 cfu) of bacteria is likely to be 1000-fold less than that loaded on the tines.
Study design and statistics. We did not know whether lesion formation at 2 sites in an individual subject would be statistically independent. If lesion formation was not independent, then the subject would be the unit of analysis to determine the infection rate. Thus, we enrolled 20 volunteers to obtain sufficient precision to estimate the infection rate within 15%, assuming an underlying rate of 80%, using a one-sided 95% confidence interval (CI). If lesion formation could be considered independent within a subject, data from 40 sites could be used in the statistical analysis.
To study the evolution of the host response (see [8] elsewhere in this issue), 8 volunteers were assigned to biopsy 1 day or 4 days after inoculation. Twelve volunteers were observed for a maximum of 2 weeks or until they achieved the clinical end point. The clinical end point was defined as the resolution of infection at both sites or development of a painful or pruritic pustule. On the basis of previous data, we hypothesized that the pustule formation rate for an EDD of 18-44 cfu would be 70% and that lesion outcome at 2 sites in 1 subject would be statistically independent. If lesion outcome was independent within a subject, data from all 24 sites could be used in a one-tailed exact binomial test to examine if pustule formation occurred 70% of the time.
Clinical observations. Volunteers were examined daily Monday through Friday and once on weekends, as described previously [6, 7] . At each visit, surface cultures were obtained from each site [7] .
Biopsies were obtained with a punch forceps [6, 7] . Some specimens were divided in quarters and cultured semiquantitatively [6, 7] . Other biopsies were minced for T cell isolation [8] , and residual tissue was plated on chocolate agar plates. Subjects were treated with oral ciprofloxacin (500 mg) immediately after biopsy and 12 h later. Subjects were also treated with ciprofloxacin if disease resolved.
Results
Human subjects. Twenty-nine adults were enrolled in the study (13 men, 16 women; 8 black, 20 white, 1 Hispanic; mean age years). One volunteer withdrew from the study 34.3 ‫ע‬ 8 prior to inoculation. Another was excluded because she was taking ibuprofen regularly for arthritis.
Clinical response to experimental infection. Each volunteer was inoculated with 2 doses of live and 1 dose of heat-killed H. ducreyi 35000HP. Four volunteers received a lower EDD (4 or 11 cfu) than the target dose. Erythematous papules developed at 7 of 8 sites inoculated with live H. ducreyi and resolved in 2 to 7 days. These subjects were treated with ciprofloxacin, released from the study, and excluded from further analysis.
Twenty volunteers were challenged with the target EDD (range, 18-44 cfu; , ) of 35000HP (table mean ‫ע‬ SD 27.5 ‫ע‬ 9.8 1). In an individual subject, lesion formation was sometimes discordant. Concordance did not differ from that expected by chance, and sites were assumed independent. Thus, the infection rate was determined based on all sites inoculated. Papules developed in 1 day at 38 (95%) of 40 sites (95% CI, 83.1%-99.4%). No lesions occurred at sites inoculated with heat-killed bacteria.
Eight subjects were assigned to biopsy 1 day and 4 days after inoculation. Since infection was terminated prior to achievement of the clinical end point, data from these 8 subjects were not used to calculate lesion outcome.
Twelve subjects were followed for 2 weeks or until they achieved the clinical end point. Nine of the 12 had concordant outcomes; in other words, both papules resolved or both papules evolved into pustules. Two of the 12 subjects had discordant outcomes; a painful pustule developed at 1 site while the second lesion resolved or remained a papule. One of the 12 subjects developed a papule at only 1 site, which resolved in 3 days. Since lesion outcome in the 2 sites in individual subjects appeared independent, the pustule formation rate was based on 23 papules followed to end point. Six (27.3%) of the papules resolved in 3-5 days ( ), and 1 papule remained at the 4.3 ‫ע‬ 1 papular stage through the observation period. The other 16 papules evolved into pustules in 2-5 days ( ). The pustule 3.5 ‫ע‬ 1 formation rate was 69.6% (95% CI, 47.1%-86.8%). None of the pustules resolved within 3-11 days ( ) of 7.2 ‫ע‬ 2.4 observation.
Recovery of H. ducreyi from experimental lesions. The recovery rate of H. ducreyi from surface cultures ranged from 14% to 41.2% between day 1 and day 7 (figure 1). H. ducreyi was recovered intermittently (67 of 174 cultures) from 11 (65%) of 17 lesions that did not resolve. However, none of the 6 papules that resolved were culture-positive (0 of 27 cultures obtained when disease was present). The difference in the recovery rate of H. ducreyi from lesions that did not resolve and from lesions that resolved was statistically significant (Fisher's exact test, ). Cultures ( ) of sites inoculated with P ϭ .014 n ϭ 104 heat-killed bacteria were sterile.
H. ducreyi was recovered from 0 of 4 papules and 3 of 5 pustules that were semiquantitatively cultured. The range of H. ducreyi recovered varied from to cfu per 2 5 6.50 ϫ 10 3.75 ϫ 10 gram of tissue. H. ducreyi was recovered from 1 of 3 papules and 9 of 10 pustules that were cultured qualitatively. Hence, the overall recovery rate of H. ducreyi from all biopsies was 80% (12/15) for pustules and 14% (1/7) for papules (Fisher's exact test, ). P ϭ .007 Complications. Three volunteers were inoculated with a mixed culture of H. ducreyi and Pseudomonas aeruginosa. The Pseudomonas isolate was sensitive to ciprofloxacin, and the EDD of the contaminants was 10 cfu. These volunteers developed disease typical of experimental chancroid. When the contamination was noted by subculturing the inoculum, the volunteers were treated with 2 doses of oral ciprofloxacin. Their lesions resolved, and the subjects were released from the study.
All subjects were contacted 6 months after participation in the study. Two volunteers developed hypertrophic scars at the biopsy sites and were treated with intralesional injections of triamcinolone. The hypertrophic scars became flat after treatment.
Discussion
In dose-response trials with H. ducreyi 35000, papule and pustule formation rates could not be determined due to the small sample size. In this study, inoculation of a mean EDD of cfu of 35000HP caused papule formation at 95% 27.5 ‫ע‬ 9.8 of 40 sites (95% CI, 83.1%-99.4%) infected with live bacteria. For 23 papules followed to the clinical end point, the pustule formation rate was 69% (95% CI, 47.1%-86.6%). H. ducreyi 35000 and 35000HP had similar outer membrane and lipooligosaccharide profiles and growth rates and appeared to be equally virulent based on historical controls in the human challenge model.
Several subjects followed to clinical end point had discordant outcomes, where 1 papule developed into a pustule while a second papule resolved or remained at the papular stage. None of the pustules resolved within the observation period of 3-11 days. These findings suggest that local factors play a role in the resolution of the disease and that the immune system may clear disease at the papular but not the pustular stage.
We recovered H. ducreyi intermittently from the surface of 11 of 17 pustules and nonresolving papules and from 0 of 6 papules that resolved. Thus, H. ducreyi was shed intermittently from sites with established infection and not from sites where infection was transient. H. ducreyi was recovered from 3 of 5 pustules and 0 of 4 papules that were quantitatively cultured.
An EDD of 18-44 cfu was injected into the skin of the subjects, and entire pustules were estimated to contain to 2 7.2 ϫ 10 recoverable cfu. The overall recovery rate of H. du-3 6.0 ϫ 10 creyi from biopsies was 80% for pustules and 14% for papules. Taken together, the data indicate that H. ducreyi replicate between the papular and pustular stages.
Inadvertent infection with a mixed bacterial culture occurred once during this study. The contaminant was probably introduced into the inoculum during processing of the mid-log phase culture. We revised our inoculum preparation protocol and have safely infected an additional 45 volunteers in 19 different iterations. However, our informed consent statements note the potential risk of inadvertent infection with contaminants.
None of the volunteers developed fever or lymphadenopathy. No secondary transmission occurred in 125 patient-days of observations. However, 2 volunteers developed hypertrophic scars at sites that were biopsied. To date, we have completed several trials of human experimental infection with H. ducreyi [6] [7] [8] [9] [10] . Of 65 subjects who were challenged, 53 underwent biopsy, and 7 (13.2% of those biopsied) formed hypertrophic scars. Hypertrophic scars formed only where clinical disease was present and a biopsy was done. Of 15 blacks who were biopsied, 5 (33%) formed hypertrophic scars; of 36 whites who were biopsied, 2 (5.5%) formed hypertrophic scars ( ). Seven of P ϭ .018 28 women formed hypertrophic scars, whereas 0 of 25 men formed hypertrophic scars ( ). Hypertrophic scars are P ϭ .034 known to form more commonly in blacks and Asians than in whites [11, 12] , and there is no known association between gender and hypertrophic scarring [11] . Thus, the increased prevalence in minorities is probably significant, while the gender differences may be spurious. We now include the above data in our revised informed consent statements. At the intake visit, volunteers are shown pictures of scars that result from participation in the study, including those with good cosmetic results and hypertrophic scars before and after treatment with intralesional triamcinolone. Volunteers are asked not to participate in the studies if the possible cosmetic results are unacceptable to them.
In summary, these data have laid the foundation for other experimental infection trials with H. ducreyi. An EDD of ≤15 cfu of H. ducreyi generally causes only transient infection [7] . Inoculation of an EDD of 100-1000 cfu causes a pustule formation rate of 100%, but disease progresses too rapidly to mimic natural infection [6] . Inoculation of ∼30 cfu causes a papule formation rate of 95% and a pustule formation rate of 69%. Thus, for chemoprophylaxis or vaccine trials, subjects are inoculated at 2 sites with 30-60 cfu to ensure that a susceptible subject will become infected [9] . Lesion outcome at multiple sites inoculated with the same isolate in an individual subject may be independent. For comparison of an isogenic mutant and its parent, subjects are infected at multiple sites with the parent and the mutant, as opposed to inoculating subjects with 1 dose of each isolate [10] . If the mutant is avirulent at an EDD of 30-60 cfu, the EDD of the mutant can be increased into the 10 2 to 10 3 cfu range to assess if the isogenic mutant is severely impaired in virulence. However, the EDD of the parent must be held in the 30 cfu range or disease will progress at these sites too rapidly to allow sufficient time to observe a subject.
